New Pill-and-IV combo takes on bile duct cancer in small trial

NCT ID NCT07146646

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial is testing a combination of two chemotherapy drugs—trifluridine/tipiracil (pills) and oxaliplatin (IV)—in people with advanced or metastatic biliary tract cancer whose first treatment stopped working. The goal is to see if this combo can control the cancer better than the standard second-line therapy. About 27 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
trifluridine/tipiracil (pills) plus oxaliplatin (IV)
What this could lead to
If this works, it could offer a new second-line treatment option for people with advanced biliary tract cancer, helping to control the disease longer.
What could go wrong
This is a small, early-phase trial with only 27 participants. The combination may not work better than existing treatments, and side effects could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic Taussig Cancer Center, Case Comprehensive Cancer Center

    NOT_YET_RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center

    RECRUITING

    Cleveland, Ohio, 44106, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.